Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Exenatide + glucagon refers to a combination of two peptide hormones with distinct but potentially complementary mechanisms. Exenatide is a synthetic analog of glucagon-like peptide-1 (GLP-1) and acts as a GLP-1 receptor agonist, increasing glucose-dependent insulin secretion, suppressing inappropriate glucagon secretion, delaying gastric emptying, and reducing food intake. It is primarily used for the management of type 2 diabetes mellitus[1][2][5]. Glucagon itself is a hormone that raises blood glucose levels by stimulating hepatic glucose production; it is typically used in the treatment of severe hypoglycemia. While both agents are individually approved drugs, there is no evidence from the provided sources or current clinical practice guidelines that an exenatide + glucagon fixed-dose combination product exists or has been developed for any indication.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on exenatide + glucagon.